Previous 10 | Next 10 |
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
Shares of Accolade (NASDAQ: ACCD) were up as much as 25% for the week early Friday, according to data provided by S&P Global Market Intelligence . The stock closed last week at $7.43 a share, and then rose to as high as $10.01 on Tuesday. It saw a 52-week low of $4.61 and a 52-wee...
Summary The US healthcare system is hard to navigate. ACCD's strong competitive advantage is its proprietary platform. 3Q23 demonstrated solid bookings and growth. Investment thesis I recommend going long Accolade ( ACCD ). The challenges faced by individuals navig...
Accolade ( NASDAQ: ACCD ) stock rose ~23% on Tuesday after FQ3 2023 revenue grew 9% Y/Y and the company provided outlook for fiscal '23 and '24. FQ3 revenue increased to $90.95M, compared to $83.45M in FQ3 fiscal 2022. GAAP EPS of -$0.56, compared to $0.31 in the...
Accolade, Inc. (ACCD) Q3 2023 Earnings Conference Call January 09, 2023 04:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investo...
The following slide deck was published by Accolade, Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Accolade, Inc. 2023 Q3 - Results - Earnings Call Presentation
Accolade press release ( NASDAQ: ACCD ): FQ3 GAAP EPS of -$0.56 beats by $0.06 . Revenue of $90.9M (+8.9% Y/Y) beats by $3.37M . Sees Q4 revenue of $97M to $101M. The consensus revenue estimate is $101.71M. Sees Q4 adj. EBITDA between loss of $1M to earnings of...
Fiscal third quarter 2023 revenue of $90.9 million, a 9% increase compared to fiscal third quarter 2022 revenue of $83.5 million SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2022....
Accolade ( NASDAQ: ACCD ) is scheduled to announce Q3 earnings results on Monday, January 9th, after market close. The consensus EPS Estimate is -$0.43 (-238.7% Y/Y) and the consensus Revenue Estimate is $87.53M (+4.9% Y/Y). Over the last 1 year, ACCD has beaten EPS estimate...
Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 50.0% to $0.495 on volume of 360,218,139 shares NVIDIA Corporation (NVDA) fell 0.4% to $123.54 on volume of 307,578,749 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) rose 8.1% to $0.3343 on vol...